Abstract
Objective of the study Body size based dosing is often used for prescribing anticancer drugs. However the scientific and the clinical rationales of this historical method have recently been criticized. As a result, alternative dosing strategies have been suggested, as flat-fixed dosing regimens, but not implemented in routine practice. Dose standardisation is a first step in order to rationalise chemotherapy dose calculation. A new method, derived from dose-banding, was developed, taking into account prescription and economic criteria. Setting Feasibility and interest of this concept were studied in two French cancer centres Institut Curie and Hôpital Saint-Louis. Main outcome measures The aim of our study was to assess dose standardisation of expensive anticancer drugs in objectives of quality and economy. Method Nine candidate drugs were selected and standardized rounded doses (SRD) were proposed. To determine the specific standard doses of these two centres, two theoretical and practical methods were applied, and then, their results were compared. For each anticancer drug the objective was to fix SRD in order to cover all the doses most frequently prescribed. Results It has been possible to propose SRD for six of the nine drugs. These SRD have been implemented with the agreement of the medical staff. These doses are, whenever possible, rounded to the nearest vial size, or correspond to a combination of the different strength of the commercial drug. Conclusion Our study shows that dose standardisation is a help to optimise the productivity and improve the organisation of the preparation unit.
Similar content being viewed by others
References
DuBois D, DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–71.
Pinkel D. Cancer chemotherapy and body surface area. J Clin Oncol. 1998;16:3714–5.
Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219–44.
Crawford JD, Terry ME, Rourke GM. Simplification of drug dosage calculation by application of the surface area principle. Pediatrics. 1950;5:783–90.
Wang Y, Moss J, Thisted R. Predictors of body surface area. J Clin Anesth. 1992;4:4–10.
Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14:2590–611.
Reilly JJ, Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol. 1993;32:411–8.
Newell DR. Getting the right dose in cancer chemotherapy–time to stop using surface area ? Br J Cancer. 2002;86:1207–8.
Markman M. ‘Flat-fixed dosing’ of chemotherapy: a concept whose time has come? Curr Oncol Rep. 2005;7:1–2.
Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst. 1990;82:323–5.
Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002;38:1677–84.
Gurney H. I don’t underdose my patients, do I? Lancet Oncol. 2005;6:637–8.
Plumridge RJ, Sewell GJ. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health Syst Pharm. 2001;58:1760–4.
Loos WJ, de Jongh FE, Sparreboom A, et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol. 2006;24:1499–506.
Vigneron J. Stability studies of drugs used in oncology: the role of the hospital pharmacist. Eur J Hosp Pharm Pract. 2006;12:75–6.
de Lemos ML, Hamata L. Stability issues of parenteral chemotherapy drugs. J Oncol Pharm Pract. 2007;13:27–31.
Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001;19:171–7.
Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. J Natl Cancer Inst. 2002;94:1883–8.
Leveque D. Use of body weight and body surface area in dosing of anticancer agents in adult patients. Bull Cancer. 2007;94:647–51.
Kaestner SA, Sewell GJ. Chemotherapy dosing part II: alternative approaches and future prospects. Clin Oncol (R Coll Radiol). 2007;19:99–107.
Baker JP, Jones SE. Rationalisation of chemotherapy services in the University Hospital Birmingham National Health Science Trust. J Oncol Pharm Practice. 1998;4:10–4.
Leach RH, Whitmarsh S, Partridge C, Potter SR. New cytotoxics production unit at University hospital, Birmingham. Hosp Pharm. 2000;7:109–10.
MacLean F, MacIntyre J, McDade J, Moyes D. Dose banding of chemotherapy in the Edinburgh Cancer Centre. Pharm J. 2003;270:691–3.
Leth-Miller D. Dose-banding of gemcitabine. Eur J Hosp Pharm Pract. 2007;2:52.
Hirte HW, Kagoma S, Zhong L, et al. Dose banding of chemotherapy doses at the Juravinski Cancer Centre. J Clin Oncol. 2006;24:6099. (abstract).
Kaestner S, Sewell G. Dose-banding of carboplatin: rationale and proposed banding scheme. J Oncol Pharm Pract. 2007;13:109–17.
Kaestner S, Sewell GJ. A National Survey Investigating UK Prescribers’ Opinions on Chemotherapy Dosing and ‘Dose-Banding’. Clin Oncol (R Coll Radiol). 2009;21:320–8.
Bonnabry P, Cingria L, Ackermann M, Sadeghipour F, Bigler L, Mach N. Use of prospective risk analysis method to improve the safety of the cancer chemotherapy process. Int J Qual Health Care. 2005;18:9–16.
Chen CS, Seidel K, Armitage JO, et al. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 1997;3:331–40.
Dooley MJ, Singh S, Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer. 2004;12:653–6.
Kaestner S, Sewell G. Pharmacoeconomic aspects of dose-banding. Hosp Pharm Eur. 2006;26:33–4.
Kaestner S, Walker V, Roberts S, Perren T, Sewell G. Clinical and pharmacokinetic (pk) study on “dose-banded” and individual-dose chemotherapy: An interim report. J Oncol Pharm Practice. 2004;10:100.
Gillian A. British Oncology Pharmacy Association: www.bopawebsite.org. Toolkit: How to implement dose banding of chemotherapy. Accessed on 08/09/2008.
Acknowledgments
The authors would like to thank Dr Sandy Blondeel and Sylvie Carrie for their contribution.
Funding
None.
Conflicts of interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pouliquen, AL., Escalup, L., Jourdan, N. et al. Dose standardisation of anticancer drugs. Int J Clin Pharm 33, 221–228 (2011). https://doi.org/10.1007/s11096-010-9478-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-010-9478-6